# A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

> **NCT06558279** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **argenx** · enrollment: 141 (actual)

## Conditions studied

- Myasthenia Gravis, Ocular

## Interventions

- **COMBINATION_PRODUCT:** Efgartigimod PH20 SC
- **OTHER:** Placebo PH20 SC

## Key facts

- **NCT ID:** NCT06558279
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-18
- **Primary completion:** 2026-01
- **Final completion:** 2027-12
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06558279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06558279, "A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT06558279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*